These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37721470)

  • 1. The Cyclooxygenase 2 Inhibitor Etoricoxib as Adjunctive Therapy in Tuberculosis Impairs Macrophage Control of Mycobacterial Growth.
    Nore KG; Louet C; Bugge M; Gidon A; Jørgensen MJ; Jenum S; Dyrhol-Riise AM; Tonby K; Flo TH
    J Infect Dis; 2024 Mar; 229(3):888-897. PubMed ID: 37721470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors.
    Jøntvedt Jørgensen M; Jenum S; Tonby K; Mortensen R; Walzl G; Du Plessis N; Dyrhol-Riise AM
    J Leukoc Biol; 2021 Jul; 110(1):177-186. PubMed ID: 33155730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.
    Jøntvedt Jørgensen M; Nore KG; Aass HCD; Layre E; Nigou J; Mortensen R; Tasken K; Kvale D; Jenum S; Tonby K; Dyrhol-Riise AM
    Front Cell Infect Microbiol; 2021; 11():669623. PubMed ID: 34307194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients.
    Jenum S; Tonby K; Rueegg CS; Rühwald M; Kristiansen MP; Bang P; Olsen IC; Sellæg K; Røstad K; Mustafa T; Taskén K; Kvale D; Mortensen R; Dyrhol-Riise AM
    Nat Commun; 2021 Nov; 12(1):6774. PubMed ID: 34811370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host-directed therapy with amiodarone in preclinical models restricts mycobacterial infection and enhances autophagy.
    Kilinç G; Boland R; Heemskerk MT; Spaink HP; Haks MC; van der Vaart M; Ottenhoff THM; Meijer AH; Saris A
    Microbiol Spectr; 2024 Aug; 12(8):e0016724. PubMed ID: 38916320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TREM2 Promotes Immune Evasion by Mycobacterium tuberculosis in Human Macrophages.
    Dabla A; Liang YC; Rajabalee N; Irwin C; Moonen CGJ; Willis JV; Berton S; Sun J
    mBio; 2022 Aug; 13(4):e0145622. PubMed ID: 35924849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Oral Liposomal Glutathione and In Vitro Everolimus in Altering the Immune Responses against
    To K; Cao R; Yegiazaryan A; Owens J; Sasaninia K; Vaughn C; Singh M; Truong E; Sathananthan A; Venketaraman V
    Biomol Concepts; 2021 May; 12(1):16-26. PubMed ID: 33966361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Tumor Necrosis Factor Alpha and Interleukin 6 Auto-paracrine Signaling Loop Controls Mycobacterium avium Infection via Induction of IRF1/IRG1 in Human Primary Macrophages.
    Gidon A; Louet C; Røst LM; Bruheim P; Flo TH
    mBio; 2021 Oct; 12(5):e0212121. PubMed ID: 34607464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection.
    Tonby K; Wergeland I; Lieske NV; Kvale D; Tasken K; Dyrhol-Riise AM
    BMC Infect Dis; 2016 Oct; 16(1):599. PubMed ID: 27776487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactic acid bacteria enhance autophagic ability of mononuclear phagocytes by increasing Th1 autophagy-promoting cytokine (IFN-gamma) and nitric oxide (NO) levels and reducing Th2 autophagy-restraining cytokines (IL-4 and IL-13) in response to Mycobacterium tuberculosis antigen.
    Ghadimi D; de Vrese M; Heller KJ; Schrezenmeir J
    Int Immunopharmacol; 2010 Jun; 10(6):694-706. PubMed ID: 20381647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-1178 regulates mycobacterial survival and inflammatory responses in Mycobacterium tuberculosis-infected macrophages partly via TLR4.
    Shi G; Mao G; Xie K; Wu D; Wang W
    J Cell Biochem; 2018 Sep; 119(9):7449-7457. PubMed ID: 29781535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating macrophage function to reinforce host innate resistance against
    Park HE; Lee W; Choi S; Jung M; Shin MK; Shin SJ
    Front Immunol; 2022; 13():931876. PubMed ID: 36505429
    [No Abstract]   [Full Text] [Related]  

  • 16. Priming of innate antimycobacterial immunity by heat-killed
    Luukinen H; Hammarén MM; Vanha-Aho LM; Svorjova A; Kantanen L; Järvinen S; Luukinen BV; Dufour E; Rämet M; Hytönen VP; Parikka M
    Dis Model Mech; 2018 Jan; 11(1):. PubMed ID: 29208761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate cytokine profiling of bovine alveolar macrophages reveals commonalities and divergence in the response to Mycobacterium bovis and Mycobacterium tuberculosis infection.
    Magee DA; Conlon KM; Nalpas NC; Browne JA; Pirson C; Healy C; McLoughlin KE; Chen J; Vordermeier HM; Gormley E; MacHugh DE; Gordon SV
    Tuberculosis (Edinb); 2014 Jul; 94(4):441-50. PubMed ID: 24882682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunosuppressive effects of a novel recombinant LipQ (Rv2485c) protein of Mycobacterium tuberculosis on human macrophage cell lines.
    Kumar A; Manisha ; Sangha GK; Shrivastava A; Kaur J
    Microb Pathog; 2017 Jun; 107():361-367. PubMed ID: 28412202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions.
    Amaral EP; Conceição EL; Costa DL; Rocha MS; Marinho JM; Cordeiro-Santos M; D'Império-Lima MR; Barbosa T; Sher A; Andrade BB
    BMC Microbiol; 2016 Oct; 16(1):251. PubMed ID: 27793104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host-directed anti-mycobacterial activity of colchicine, an anti-gout drug, via strengthened host innate resistance reinforced by the IL-1β/PGE
    Kwon KW; Kim LH; Kang SM; Lee JM; Choi E; Park J; Hong JJ; Shin SJ
    Br J Pharmacol; 2022 Aug; 179(15):3951-3969. PubMed ID: 35301712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.